{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:15:56Z","timestamp":1791875756860,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,9]],"date-time":"2027-06-09T00:00:00Z","timestamp":1812499200000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cardfail.2026.01.024","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:18:32Z","timestamp":1776867512000},"page":"1118-1133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heart Failure With Mildly Reduced Ejection Fraction: A Heart Failure Society of America Scientific Statement"],"prefix":"10.1016","volume":"32","author":[{"given":"JANE E.","family":"WILCOX","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LARS H.","family":"LUND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZACHARY L.","family":"COX","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JENNIFER E.","family":"HO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAROLYN S.P.","family":"LAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KAVITA","family":"SHARMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-0596","authenticated-orcid":false,"given":"BARRY A.","family":"BORLAUG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.01.024_bib0001","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/ejhf.159","article-title":"The middle child in heart failure: heart failure with mid-range ejection fraction (40\u201350%)","volume":"16","author":"Lam","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0002","first-page":"1279","article-title":"Fussing over the middle child: heart failure with mid-range ejection fraction","volume":"135","author":"Lam","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0003","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0004","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0006","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0007","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0008","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Disease","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0009","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0010","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.15420\/cfr.2023.05","article-title":"Global public health burden of heart failure: an updated review","volume":"9","author":"Shahim","year":"2023","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0011","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ejhf.890","article-title":"Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0012","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0013","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes","volume":"126","author":"Steinberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0014","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0015","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction\u2014a report from the CHART-2 Study","volume":"19","author":"Tsuji","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0016","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0017","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ehf2.12455","article-title":"Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry(R)","volume":"6","author":"Ibrahim","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2023.11.008","article-title":"Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure","volume":"267","author":"Savarese","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0019","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11897-014-0220-x","article-title":"Understanding the epidemic of heart failure: past, present, and future","volume":"11","author":"Dunlay","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0020","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0021","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/ejhf.1091","article-title":"Predictors and outcomes of heart failure with mid-range ejection fraction","volume":"20","author":"Bhambhani","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0022","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cardfail.2022.10.424","article-title":"Incident heart failure with mildly reduced ejection fraction: frequency, characteristics, and outcomes","volume":"29","author":"Kumar","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0023","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC Scientific Statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875","article-title":"Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study","volume":"10","author":"Vedin","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0025","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0026","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0027","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0028","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ahj.2014.07.008","article-title":"Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population","volume":"168","author":"Cheng","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0029","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0030","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/ejhf.3230","article-title":"Cause-specific death in heart failure across the ejection fraction spectrum: a comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry","volume":"26","author":"Settergren","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0031","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2408","article-title":"A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction\u2014insights from the ESC-HFA EORP Heart Failure Long-Term Registry","volume":"24","author":"Kaplon-Cieslicka","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2023.100031","article-title":"Heart transplant outcomes in restrictive cardiomyopathy: UNOS registry analysis of the last three decades","volume":"3","author":"Miklin","year":"2024","journal-title":"JHLT Open"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0033","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0034","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure and preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0036","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0037","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacc.2009.05.013","article-title":"Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction","volume":"54","author":"Borlaug","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0038","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jacc.2017.06.046","article-title":"Geometry as a confounder when assessing ventricular systolic function: comparison between ejection fraction and strain","volume":"70","author":"Stokke","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0039","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/eurheartj\/ehv510","article-title":"Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure","volume":"37","author":"Cikes","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0040","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jacc.2011.09.062","article-title":"Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy","volume":"59","author":"Schwartzenberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0041","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0002-8703(03)00248-5","article-title":"Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods","volume":"146","author":"McGowan","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0042","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/ehjci\/jeaa206","article-title":"Test-retest reliability of left and right ventricular systolic function by new and conventional echocardiographic and cardiac magnetic resonance parameters","volume":"22","author":"Houard","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0043","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ejhf.1040","article-title":"Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction","volume":"20","author":"Bajaj","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0044","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0045","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ejhf.2576","article-title":"Left ventricular ejection fraction as the primary heart failure phenotyping parameter","volume":"24","author":"Lund","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0046","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.jacc.2024.03.373","article-title":"More evidence that HF with normal EF is distinct from HF below normal EF","volume":"83","author":"Hage","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0047","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/ehjci\/jeac204","article-title":"Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction","volume":"24","author":"Brown","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0048","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ejhf.2513","article-title":"Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction","volume":"24","author":"Jin","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0049","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","article-title":"Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0050","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2018.05.042","article-title":"Dynamic trajectories of left ventricular ejection fraction in heart failure","volume":"72","author":"Lupon","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0051","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejections","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0052","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/jama.2021.24674","article-title":"Prevalence and cumulative risk of familial idiopathic dilated cardiomyopathy","volume":"327","author":"Huggins","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0053","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0054","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jacc.2019.06.055","article-title":"Natriuretic peptide response and outcomes in chronic heart failure with reduced ejection fraction","volume":"74","author":"Januzzi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0055","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2018.08.2184","article-title":"Economic and quality-of-life outcomes of natriuretic peptide-guided therapy for heart failure","volume":"72","author":"Mark","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0056","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0057","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.124.072156","article-title":"Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting","volume":"151","author":"Reddy","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255271","article-title":"Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction","volume":"16","author":"Lokaj","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2023.12.006","article-title":"Cardiac troponin in patients with light chain and transthyretin cardiac amyloidosis: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"De Michieli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0060","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s12872-021-02386-8","article-title":"The absolute and relative changes in high-sensitivity cardiac troponin I are associated with the in-hospital mortality of patients with fulminant myocarditis","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0061","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009841","article-title":"Baseline longitudinal strain predicts recovery of left ventricular ejection fraction in hospitalized patients with nonischemic cardiomyopathy","volume":"7","author":"Swat","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0062","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0063","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2013.1363","article-title":"Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy","volume":"309","author":"Gulati","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0064","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/CIRCIMAGING.113.000438","article-title":"Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study","volume":"6","author":"Masci","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0065","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0066","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/CIRCULATIONAHA.119.043964","article-title":"OUTSMART HF: a randomized controlled trial of routine versus selective cardiac magnetic resonance for patients with nonischemic heart failure (IMAGE-HF 1B)","volume":"141","author":"Paterson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0067","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1253\/circj.CJ-19-1176","article-title":"Prognosis and clinical characteristics of dilated cardiomyopathy with family history via pedigree analysis","volume":"84","author":"Marume","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0068","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cardfail.2021.07.012","article-title":"Hemodynamics for the heart failure clinician: a state-of-the-art review","volume":"28","author":"Hsu","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0069","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0070","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0071","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0072","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0073","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0074","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0075","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0076","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0077","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0078","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0080","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0081","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0082","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2014.15241","article-title":"Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction","volume":"312","author":"Lund","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0083","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cardfail.2021.04.015","article-title":"Association between beta-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF Registry","volume":"27","author":"Meyer","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0084","doi-asserted-by":"crossref","first-page":"L10","DOI":"10.1093\/eurheartjsupp\/suac113","article-title":"The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?","volume":"24","author":"Docherty","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0085","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0086","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","article-title":"Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction","volume":"114","author":"Borlaug","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0087","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jamacardio.2023.5500","article-title":"Beta-blocker withdrawal and functional capacity improvement in patients with heart failure with preserved ejection fraction","volume":"9","author":"Palau","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0088","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","article-title":"Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial","volume":"8","author":"Infeld","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0089","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2023.0675","article-title":"Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF randomized clinical trial","volume":"329","author":"Reddy","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0090","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ejhf.621","article-title":"A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis","volume":"18","author":"Girerd","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0091","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0092","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0093","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF Trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0094","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0095","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA Trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0096","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0097","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: the DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0098","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ejhf.2843","article-title":"Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction","volume":"25","author":"Popovic","year":"2023","journal-title":"Eur J Heart Failure"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0099","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1161\/CIRCULATIONAHA.110.954388","article-title":"Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum","volume":"123","author":"Borlaug","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0101","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.124.072855","article-title":"Withdrawal of guideline-directed medical therapy in patients with heart failure and improved ejection fraction","volume":"151","author":"Basile","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0102","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0103","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction","volume":"82","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0104","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0105","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0106","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cardfail.2025.01.022","article-title":"Efficacy of GLP-1 receptor agonists in patients with heart failure and mildly reduced or preserved ejection fraction: a systematic review and meta-analysis","volume":"31","author":"Waqas","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0107","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0108","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0109","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","article-title":"Percutaneous revascularization for ischemic left ventricular dysfunction","volume":"387","author":"Perera","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0110","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.jacc.2014.03.034","article-title":"Implications of coronary artery disease in heart failure with preserved ejection fraction","volume":"63","author":"Hwang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0111","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0112","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/ejhf.2630","article-title":"Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial","volume":"24","author":"Metra","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0113","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ejhf.2810","article-title":"Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis","volume":"25","author":"Graham","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0114","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0115","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehaa129","article-title":"Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction","volume":"41","author":"Bartko","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0116","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ejhf.208","article-title":"Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction","volume":"17","author":"Hai","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0117","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJMoa1210356","article-title":"Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block Trial I. Biventricular pacing for atrioventricular block and systolic dysfunction","volume":"368","author":"Curtis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0118","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.hrthm.2024.05.014","article-title":"Cardiac resynchronization therapy for patients with mild to moderately reduced ejection fraction and left bundle branch block","volume":"21","author":"Cha","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0119","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/CIRCULATIONAHA.116.026910","article-title":"Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction","volume":"135","author":"Halliday","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.024_bib0120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2017.1413","article-title":"Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction: secondary analysis of the Sudden Cardiac Death in Heart Failure Trial","volume":"2","author":"Adabag","year":"2017","journal-title":"JAMA Cardiol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642600134X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642600134X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:55:31Z","timestamp":1781002531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107191642600134X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S107191642600134X"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.01.024","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart Failure With Mildly Reduced Ejection Fraction: A Heart Failure Society of America Scientific Statement","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}